# Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

> **NCT04054193** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 103 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Fosaprepitant Dimeglumine
- **DRUG:** 5-HT3 antagonist
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04054193
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-09
- **Primary completion:** 2021-02-11
- **Final completion:** 2021-02-11
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04054193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04054193, "Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04054193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*